CA2947198C - Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest - Google Patents

Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest Download PDF

Info

Publication number
CA2947198C
CA2947198C CA2947198A CA2947198A CA2947198C CA 2947198 C CA2947198 C CA 2947198C CA 2947198 A CA2947198 A CA 2947198A CA 2947198 A CA2947198 A CA 2947198A CA 2947198 C CA2947198 C CA 2947198C
Authority
CA
Canada
Prior art keywords
cell
matriptase
polypeptide
interest
vertebrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2947198A
Other languages
English (en)
French (fr)
Other versions
CA2947198A1 (en
Inventor
Holger Laux
Sandrine Romand
Ursula Bodendorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53682742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2947198(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2947198A1 publication Critical patent/CA2947198A1/en
Application granted granted Critical
Publication of CA2947198C publication Critical patent/CA2947198C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
CA2947198A 2014-04-29 2015-04-29 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest Active CA2947198C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461985589P 2014-04-29 2014-04-29
US61/985,589 2014-04-29
US201461994310P 2014-05-16 2014-05-16
US61/994,310 2014-05-16
PCT/IB2015/053110 WO2015166427A2 (en) 2014-04-29 2015-04-29 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest

Publications (2)

Publication Number Publication Date
CA2947198A1 CA2947198A1 (en) 2015-11-05
CA2947198C true CA2947198C (en) 2023-01-17

Family

ID=53682742

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2947198A Active CA2947198C (en) 2014-04-29 2015-04-29 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest

Country Status (17)

Country Link
US (2) US11512335B2 (enExample)
EP (3) EP3536776B1 (enExample)
JP (1) JP6636453B2 (enExample)
KR (1) KR102307278B1 (enExample)
CN (1) CN106255749A (enExample)
AU (1) AU2015254913B2 (enExample)
CA (1) CA2947198C (enExample)
DK (2) DK3137595T3 (enExample)
ES (2) ES2968879T3 (enExample)
IL (1) IL248184B (enExample)
LT (2) LT3536776T (enExample)
MX (1) MX368664B (enExample)
PL (2) PL3536776T3 (enExample)
PT (2) PT3536776T (enExample)
RU (1) RU2710726C2 (enExample)
SG (1) SG11201608358VA (enExample)
WO (1) WO2015166427A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608358VA (en) 2014-04-29 2016-11-29 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
PE20200697A1 (es) 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
US12559526B2 (en) * 2018-10-15 2026-02-24 The Regents Of The University Of California Complement component 1s (C1s) deficient cells for production of vaccines and biopharmaceutical proteins
US20220348632A1 (en) 2019-09-18 2022-11-03 Novartis Ag Nkg2d fusion proteins and uses thereof
AU2021215893A1 (en) * 2020-02-05 2022-08-25 Novartis Ag CHO cell expressing IL-15 heterodimers
CN115605592A (zh) * 2020-05-11 2023-01-13 基因泰克公司（Us） 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
CN115551519A (zh) * 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
US20250313878A1 (en) * 2022-05-19 2025-10-09 Novartis Ag IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
IE56716B1 (en) 1983-01-19 1991-11-20 Genentech Inc Method for producing human tpa and expression vectors therefor
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU2001278488A1 (en) 2000-07-25 2002-02-05 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
EP1427744B1 (en) * 2001-08-27 2007-12-26 Genentech, Inc. A system for antibody expression and assembly
WO2004031733A2 (en) * 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
US7572444B2 (en) 2004-12-20 2009-08-11 Amgen Fremont Inc. Binding proteins specific for human matriptase
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
ES2546086T3 (es) 2007-12-21 2015-09-18 Novartis Ag Sistema de selección en un cultivo de células eucariotas basado en un gen receptor de folato unido a la membrana
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
RU2535986C2 (ru) 2009-02-27 2014-12-20 Новартис Аг Система векторов экспрессии, включающая два селективных маркера
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
AU2011246503B2 (en) 2010-04-26 2013-09-26 Novartis Ag Improved cell culture medium
EP2714716B1 (en) 2011-06-02 2018-04-11 Socpra Sciences Santé Et Humaines S.E.C. Matriptase inhibitors and uses thereof against orthomyxoviridae infections
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
SG11201608358VA (en) 2014-04-29 2016-11-29 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Also Published As

Publication number Publication date
KR20160147919A (ko) 2016-12-23
PT3137595T (pt) 2019-06-19
EP3137595B1 (en) 2019-03-13
CA2947198A1 (en) 2015-11-05
LT3137595T (lt) 2019-06-25
DK3536776T3 (da) 2024-01-15
IL248184B (en) 2021-03-25
EP4332231A2 (en) 2024-03-06
WO2015166427A2 (en) 2015-11-05
ES2731246T3 (es) 2019-11-14
JP2017514484A (ja) 2017-06-08
RU2016145928A3 (enExample) 2018-12-26
BR112016024534A2 (pt) 2017-10-10
EP4332231A3 (en) 2024-05-29
LT3536776T (lt) 2024-01-25
EP3536776B1 (en) 2023-10-25
AU2015254913B2 (en) 2018-05-17
AU2015254913A1 (en) 2016-10-27
PL3137595T3 (pl) 2019-09-30
US20230323419A1 (en) 2023-10-12
KR102307278B1 (ko) 2021-09-30
RU2016145928A (ru) 2018-05-29
MX2016014222A (es) 2017-05-04
RU2710726C2 (ru) 2020-01-10
MX368664B (es) 2019-10-10
PT3536776T (pt) 2024-01-12
ES2968879T3 (es) 2024-05-14
EP3137595A2 (en) 2017-03-08
JP6636453B2 (ja) 2020-01-29
PL3536776T3 (pl) 2024-03-25
IL248184A0 (en) 2016-11-30
SG11201608358VA (en) 2016-11-29
DK3536776T5 (da) 2024-09-02
EP3536776A1 (en) 2019-09-11
US11512335B2 (en) 2022-11-29
CN106255749A (zh) 2016-12-21
WO2015166427A3 (en) 2016-01-14
DK3137595T3 (da) 2019-06-17
US20170044587A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
US20230323419A1 (en) Vertebrate cells and methods for recombinantly expressing a polypeptide of interest
CA2934411C (en) Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3083677B1 (en) Novel eukaryotic cells and methods for recombinantly expressing a product of interest
BR112016024534B1 (pt) Métodos para produzir de forma recombinante um polipeptídeo de interesse, para produzir uma célula de vertebrado isolada, e para selecionar uma célula, bem como uso de uma célula de vertebrado
US20250313878A1 (en) IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200403

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241221

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241221

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260317